Women’s telehealth platform Midi Health has unveiled a new brand identity as it expands beyond menopause care into a broader range of women’s health services.
Earlier this year, Midi secured a $100 million funding round at a $1 billion valuation. With more than 450,000 patients served and a suite of products and treatments, the company is adding clinical pathways beyond midlife, including metabolic health and PMOS support.
Entering a new era, the updated brand and website are designed to bring Midi’s expanded care options into one platform. Patients can now access options spanning clinical labs, hormone therapy, and supplements, while Midi says its AI-powered clinical tools help providers deliver personalized, evidence-based care while keeping clinical judgment and empathy at the center of care.
“We are laying the foundation for Midi’s next era of growth,” said Joanna Strober, Midi Health CEO and Co-Founder. “As the lines between primary and specialty care begin to converge, we are perfectly positioned to take on both the specialized and primary care needs of our patients. We’ve earned women’s trust by delivering compassionate, effective, clinician-led care through midlife, and we’re now applying that same model to more and new clinical care types.”
The visual refresh also marks a departure from the softer aesthetic often associated with women’s health, using bold typography and high-contrast colors to reflect the company’s broader ambition.
As Midi expands its clinical scope, the company is positioning itself less as a menopause specialist and more as a longitudinal healthcare partner for women across life stages.
“Our patients are looking for a highly personalized, trusted healthcare partner not just at one moment in their lives, but across every stage, and that’s what we’re building at Midi,” said Midi Health Chief Marketing Officer Melissa Waters.
